DALLAS--(BUSINESS WIRE)--Peloton Therapeutics, Inc., announced today that it will present first-in-human Phase 1 clinical data for its lead investigational oncology agent and hypoxia-inducible factor-2α (HIF-2α) inhibitor, PT2977, at the annual meeting of the American Society of Clinical Oncology (ASCO) taking place June 1-5, 2018 in Chicago. PT2977 is a selective, orally available HIF-2α antagonist with improved potency and a superior pharmacokinetics profile relative to Peloton’s first-generation agent PT2385, which had demonstrated clinical activity in patients with clear cell renal cell carcinoma (ccRCC) as reported in a study published in the Journal of Clinical Oncology (JCO).
The ASCO abstract (#2508) titled “A First-in-Human Phase 1 Dose-Escalation Trial of the Oral HIF-2α Inhibitor PT2977 in Patients with Advanced Solid Tumors” was accepted for an oral presentation to be delivered on Friday, June 1, 2018 at 5:09 p.m., Eastern Time. In this Phase 1 dose-escalation trial, patients with locally advanced or metastatic solid tumors, who had received at least one prior systemic therapy, were treated with PT2977 once daily. The primary objective of the study was to determine the recommended Phase 2 dose and evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of PT2977. PT2977 had a favorable safety profile and demonstrated early evidence of clinical activity.
“HIF-2α is a transcription factor that has been implicated in cancer initiation, progression, and metastasis especially in renal cell carcinoma. We are excited about the availability of a once-daily oral, potent, and selective inhibitor of HIF-2α,” said Kyriakos P. Papadopoulos, Co-Director of Clinical Research, START Center for Cancer Care (San Antonio, TX) and presenter of the Phase 1 data at ASCO. “PT2977 had a favorable safety, pharmacokinetics, and pharmacodynamics profile.”
Patients were treated with PT2977 in doses ranging from 20 to 160 milligrams (mg). Exposure increased with dose along with dose-dependent reductions in erythropoietin levels (a PD marker). No treatment-related, dose-limiting toxicities were observed. Anemia (13 percent) was the most common Grade 3 adverse event. Early evidence of clinical antitumor activity including radiographic response and durable disease control were observed.
“We are encouraged by the results from this Phase 1 dose-escalation study of our superior HIF-2α antagonist PT2977, which support further clinical development and evaluation of this novel agent,” said John A. Josey, Ph.D., Peloton’s Chief Executive Officer. “Based on the favorable PK and PD findings from this study, a dose of 120 mg has been selected for further clinical development and we have recently recruited 50 patients into an expansion arm to evaluate PT2977 in patients with advanced renal cell carcinoma, a malignancy with poor prognosis where effective tolerable therapies continue to be in desperate need.”
Further information on the clinical trial of PT2977 can be found on clinicaltrials.gov (Study identifier: NCT02974738).
Peloton has succeeded in creating a series of orally-available small molecules that bind to HIF-2α and inhibit its transcription of disease-promoting genes. PT2977 is a once-daily, orally-active agent that blocks hypoxia-inducible factor-2α (HIF-2α). It is a structurally-related compound designed to be more potent with less pharmacokinetics variability compared to PT2385. PT2977 has demonstrated anti-tumor activity with a favorable safety profile in an early-stage clinical study in patients with solid tumors. Given its superior pharmacokinetics profile, PT2977 is the lead agent being developed in oncology by Peloton. Peloton is currently evaluating PT2977 in an international Phase 2 trial in von Hippel-Lindau (VHL) disease-associated RCC and a Phase 1 clinical trial for the treatment of RCC.
About Peloton Therapeutics
Peloton Therapeutics, Inc. is a clinical-stage pharmaceutical company that is translating groundbreaking scientific insights into first-in-class oral medicines for patients with cancer and other serious or life-threatening conditions. The Company’s lead development program is evaluating the only clinical stage small-molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney cancer and a wide variety of other disorders. Peloton is also progressing several research programs by building upon its success in inhibiting HIF-2α, which was previously thought to be intractable using small molecules.
To learn more about Peloton Therapeutics, visit www.pelotontherapeutics.com.
© 2018 Peloton Therapeutics, Inc.
All Rights Reserved